CYP3A4: Cytochrome P450 3A4
A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on CYP3A4, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Tabimorelin | Phase 2 | — | Small molecule | InhibitorCytochrome P450 3A4 inhibitor | 0 |
- HIV infectious disease0.61
- HIV-1 infection0.58
- Chronic hepatitis C virus infection0.57
- Hepatitis C virus infection0.56
- Infection0.47
- COVID-190.42
- Cirrhosis of liver0.41
- Vitamin D-dependent rickets, type 20.40
- Viral infectious disease0.37
- Neurodegenerative disease0.37
- Hepatitis B virus infection0.35
- Tuberculosis0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL340, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P08684, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets